Glucocorticoid-induced osteoporosis evaluation, prevention, and treatment

Journal of Clinical Rheumatology

Volumn 3, Issue 2 SUPPL., 1997, Pages

  Werth, Victoria P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bisphosphonates; Calcitonin; Glucocorticoids; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; MEDROXYPROGESTERONE; PAMIDRONIC ACID; PREDNISONE; SALCATONIN; STEROID; TESTOSTERONE ENANTATE; VITAMIN D;

BONE DENSITY; BONE MINERAL; BONE PAIN; CALCIUM INTAKE; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG INDUCED DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOGONADISM; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOMALACIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHINITIS; STEROID THERAPY; VITAMIN INTAKE;

EID: 0031008567     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199704001-00016     Document Type: Conference Paper

References (44)

1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 1932;50:137-95.
2. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
3. Schaadt O, Bohr H. Loss of bone mineral in axial and peripheral skeleton in aging, prednisone treatment and osteoporosis. In: Dequeker JV, Johnston CC Jr, editors. Noninvasive bone measurements: methodological problems. Oxford: IRL Press, 1982:207-14.
4. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
5. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995;22:1055-9.
6. LoCascio V, Bonucci E, Imbimbo B. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990;8:39-51.
7. Adler RA, Rosen CJ. Glucocorticoids and osteoporosis. Endocrinol Metab Clin North Am 1994;23:641-654.
8. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265.
9. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994; 20:629-50.
10. Laan RFJM, van Riel PLCM, van de Putte LBA, van Erning LJTO, van't Hot MA, Lemmens JAM. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993;199:963-8.
11. Dobnig FH, Stepan V, Leb G, Wolf G, Buchfelder M, Krejs GJ. Recovery from severe osteoporosis following cure from ectopic ACTH syndrome caused by an appendix carcinoid. J Intern Med 1996;239:365-9.
12. Delany AM, Dong Y, Canalis E. Mechanisms of glucocorticoid action in bone cells. J Cell Biochem 1994;56:295-302.
13. Chevalley T, Strong DD, Mohan S, Bayling DJ, Linkhart TA. Evidence for a role for insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human osteoblast-like cell proliferation. Eur J Endocrinol 1996;134:591-601.
14. Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol 1996;14:199-206.
15. Godschalk MF, Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 1988;3: 113-5.
16. Emkey RD, Lindsay R, Lyssy J, Weisberg JS, Dempster DW, Shen V. The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:277-82.
17. Gough AKS, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344:23-7.
18. Lems WF, Gerrits MI, Jacobs JWG, van Vugt RM, van Rijn HJM, Bijlsma JWJ. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:288-93.
19. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995;22:1055-9.
20. Pons F, Peris P, Guanabens N, et al. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. Br J Rheumatol 1995;34:742-6.
21. Houssiau FA, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, de Deuxchasnes CN. Trabecular and cortical bone loss in systemic lupus erthematosus. Br J Rheumatol 1996;35:244-7.
22. Wahner HW, Dunn WL, Brown ML, et al. Comparison of dual-energy x-ray absorptiometry and dual photon absorptiometry for bone mineral measurements of the lumbar spine. Mayo Clin Proc 1988;63:1075-84.
23. Wasnich RD, Benfante J, Yano K, et al. Thiazide effect on the mineral content of bone. N Engl J Med 1983;309:344-7.
24. Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow-up. J Rheumatol 1996;23:995-1000.
25. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993;328:1747-52.
26. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994;37:1499-1505.
27. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1063-9.
28. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986;104:648-51.
29. Foresta C, Ruzza G, Mioni R, et al. Testosterone and bone loss in Klinefelter syndrome. Horm Metab Res 1983;15:56.
30. Reid IR, Veali AG, France JT. Glucocorticoid osteoporosis. J Asthma 1994;1:7-18.
31. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996;156:1173-7.
32. Luengo M, Picado C, Rio D, et al. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. Am Rev Respir Dis 1990;142:104-7.
33. Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987;33:35-9.
34. Reid IR, Schooler BA, Steward AW. Prevention of glucocorticoid-induced osteoporosis. J Bone Miner Res 1990;5:619-23.
35. Rosen CJ, Kessenich CR. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Drugs 1996;51:537-51.
36. Adachi JD, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid-induced bone loss. J Rheumatol 1994;21:1922-6.
37. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.
38. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
39. Gallacher SJ, Fenner JAK, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid-dependent lung disease: an open pilot study. Thorax 1992;47:932-6.
40. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988;1:143-6.
41. Reid IR, Heap SW, King AR, et al. Two-year follow-up of biphosphone (APD) treatment in steroid osteoporosis (letter). Lancet 1988;2: 1144.
42. Sebaldt RJ, Adachi JD, Bensen WG, et al. Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: two years of follow-up. Scand J Rheumatol 1996; 25(103 Suppl):91-3.
43. Diamond T, McGuiagan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995;98:459-63.
44. Liberman UA, Weiss SR, Broli J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.